Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors. / Marner, Lisbeth; Nysom, Karsten; Sehested, Astrid; Borgwardt, Lise; Mathiasen, René; Henriksen, Otto Mølby; Lundemann, Michael; Munck Af Rosenschöld, Per; Thomsen, Carsten; Bøgeskov, Lars; Skjøth-Rasmussen, Jane; Juhler, Marianne; Kruse, Anders; Broholm, Helle; Scheie, David; Lauritsen, Torsten; Forman, Julie Lyng; Wehner, Peder Skov; Højgaard, Liselotte; Law, Ian.

In: The Journal of Nuclear Medicine, Vol. 60, No. 8, 2019, p. 1053-1058.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Marner, L, Nysom, K, Sehested, A, Borgwardt, L, Mathiasen, R, Henriksen, OM, Lundemann, M, Munck Af Rosenschöld, P, Thomsen, C, Bøgeskov, L, Skjøth-Rasmussen, J, Juhler, M, Kruse, A, Broholm, H, Scheie, D, Lauritsen, T, Forman, JL, Wehner, PS, Højgaard, L & Law, I 2019, 'Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors', The Journal of Nuclear Medicine, vol. 60, no. 8, pp. 1053-1058. https://doi.org/10.2967/jnumed.118.220293

APA

Marner, L., Nysom, K., Sehested, A., Borgwardt, L., Mathiasen, R., Henriksen, O. M., ... Law, I. (2019). Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors. The Journal of Nuclear Medicine, 60(8), 1053-1058. https://doi.org/10.2967/jnumed.118.220293

Vancouver

Marner L, Nysom K, Sehested A, Borgwardt L, Mathiasen R, Henriksen OM et al. Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors. The Journal of Nuclear Medicine. 2019;60(8):1053-1058. https://doi.org/10.2967/jnumed.118.220293

Author

Marner, Lisbeth ; Nysom, Karsten ; Sehested, Astrid ; Borgwardt, Lise ; Mathiasen, René ; Henriksen, Otto Mølby ; Lundemann, Michael ; Munck Af Rosenschöld, Per ; Thomsen, Carsten ; Bøgeskov, Lars ; Skjøth-Rasmussen, Jane ; Juhler, Marianne ; Kruse, Anders ; Broholm, Helle ; Scheie, David ; Lauritsen, Torsten ; Forman, Julie Lyng ; Wehner, Peder Skov ; Højgaard, Liselotte ; Law, Ian. / Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors. In: The Journal of Nuclear Medicine. 2019 ; Vol. 60, No. 8. pp. 1053-1058.

Bibtex

@article{64f6039960c346d0ae81cd06e2938e35,
title = "Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors",
abstract = "Purpose: Complete resection is the treatment of choice for most pediatric brain tumors, but early postoperative MRI for detection of residual tumor may be misleading due to magnetic resonance imaging (MRI) signal changes caused by the operation. PET (positron emission tomography) imaging with amino acid tracers in adults increase the diagnostic accuracy for brain tumors but the literature in pediatric neurooncology is limited. A hybrid PET/MRI system is highly beneficial in children reducing the number of scanning procedures and this is to our knowledge the first larger study using PET/MRI in pediatric neurooncology. We evaluated if additional postoperative 18F-fluoro-ethyl-tyrosine (18F-FET) PET in children and adolescents would 1) improve diagnostic accuracy for the detection of residual tumor as compared to MRI alone, and 2) assist clinical management. Methods: Twenty-two patients (7 males, mean age 9.5 years, range 0-19) were included prospectively and consecutively in the study and had twenty-seven early postoperative 18F-FET PET performed preferentially in a hybrid PET/MRI system (NCT03402425). Results: Using follow-up (93{\%}) or re-operation (7{\%}) as reference standard, PET combined with MRI discriminated tumor from treatment effects with a lesion based sensitivity/specificity/accuracy (95{\%} confidence intervals) of 0.73(0.50-1.00)/1.00(0.74-1.00)/0.87(0.73-1.00) compared to MRI alone: 0.80(0.57-1.00)/0.75(0.53-0.94)/0.77(0.65-0.90), i.e. the specificity for PET/MRI was 1.00 as compared to 0.75 for MRI alone (P = 0.13). In 11 of 27 cases (41{\%}), results from the 18F-FET PET scans added relevant clinical information including one scan that directly influenced clinical management as an additional residual tumor site was identified. 18F-FET uptake in reactive changes was frequent (52{\%}) but correct interpretation was possible in all cases. Conclusion: The high specificity for detecting residual tumor suggests that supplementary 18F-FET PET is relevant in cases where re-operation for residual tumor is considered.",
author = "Lisbeth Marner and Karsten Nysom and Astrid Sehested and Lise Borgwardt and Ren{\'e} Mathiasen and Henriksen, {Otto M{\o}lby} and Michael Lundemann and {Munck Af Rosensch{\"o}ld}, Per and Carsten Thomsen and Lars B{\o}geskov and Jane Skj{\o}th-Rasmussen and Marianne Juhler and Anders Kruse and Helle Broholm and David Scheie and Torsten Lauritsen and Forman, {Julie Lyng} and Wehner, {Peder Skov} and Liselotte H{\o}jgaard and Ian Law",
note = "Copyright {\circledC} 2019 by the Society of Nuclear Medicine and Molecular Imaging, Inc.",
year = "2019",
doi = "10.2967/jnumed.118.220293",
language = "English",
volume = "60",
pages = "1053--1058",
journal = "The Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine",
number = "8",

}

RIS

TY - JOUR

T1 - Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors

AU - Marner, Lisbeth

AU - Nysom, Karsten

AU - Sehested, Astrid

AU - Borgwardt, Lise

AU - Mathiasen, René

AU - Henriksen, Otto Mølby

AU - Lundemann, Michael

AU - Munck Af Rosenschöld, Per

AU - Thomsen, Carsten

AU - Bøgeskov, Lars

AU - Skjøth-Rasmussen, Jane

AU - Juhler, Marianne

AU - Kruse, Anders

AU - Broholm, Helle

AU - Scheie, David

AU - Lauritsen, Torsten

AU - Forman, Julie Lyng

AU - Wehner, Peder Skov

AU - Højgaard, Liselotte

AU - Law, Ian

N1 - Copyright © 2019 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

PY - 2019

Y1 - 2019

N2 - Purpose: Complete resection is the treatment of choice for most pediatric brain tumors, but early postoperative MRI for detection of residual tumor may be misleading due to magnetic resonance imaging (MRI) signal changes caused by the operation. PET (positron emission tomography) imaging with amino acid tracers in adults increase the diagnostic accuracy for brain tumors but the literature in pediatric neurooncology is limited. A hybrid PET/MRI system is highly beneficial in children reducing the number of scanning procedures and this is to our knowledge the first larger study using PET/MRI in pediatric neurooncology. We evaluated if additional postoperative 18F-fluoro-ethyl-tyrosine (18F-FET) PET in children and adolescents would 1) improve diagnostic accuracy for the detection of residual tumor as compared to MRI alone, and 2) assist clinical management. Methods: Twenty-two patients (7 males, mean age 9.5 years, range 0-19) were included prospectively and consecutively in the study and had twenty-seven early postoperative 18F-FET PET performed preferentially in a hybrid PET/MRI system (NCT03402425). Results: Using follow-up (93%) or re-operation (7%) as reference standard, PET combined with MRI discriminated tumor from treatment effects with a lesion based sensitivity/specificity/accuracy (95% confidence intervals) of 0.73(0.50-1.00)/1.00(0.74-1.00)/0.87(0.73-1.00) compared to MRI alone: 0.80(0.57-1.00)/0.75(0.53-0.94)/0.77(0.65-0.90), i.e. the specificity for PET/MRI was 1.00 as compared to 0.75 for MRI alone (P = 0.13). In 11 of 27 cases (41%), results from the 18F-FET PET scans added relevant clinical information including one scan that directly influenced clinical management as an additional residual tumor site was identified. 18F-FET uptake in reactive changes was frequent (52%) but correct interpretation was possible in all cases. Conclusion: The high specificity for detecting residual tumor suggests that supplementary 18F-FET PET is relevant in cases where re-operation for residual tumor is considered.

AB - Purpose: Complete resection is the treatment of choice for most pediatric brain tumors, but early postoperative MRI for detection of residual tumor may be misleading due to magnetic resonance imaging (MRI) signal changes caused by the operation. PET (positron emission tomography) imaging with amino acid tracers in adults increase the diagnostic accuracy for brain tumors but the literature in pediatric neurooncology is limited. A hybrid PET/MRI system is highly beneficial in children reducing the number of scanning procedures and this is to our knowledge the first larger study using PET/MRI in pediatric neurooncology. We evaluated if additional postoperative 18F-fluoro-ethyl-tyrosine (18F-FET) PET in children and adolescents would 1) improve diagnostic accuracy for the detection of residual tumor as compared to MRI alone, and 2) assist clinical management. Methods: Twenty-two patients (7 males, mean age 9.5 years, range 0-19) were included prospectively and consecutively in the study and had twenty-seven early postoperative 18F-FET PET performed preferentially in a hybrid PET/MRI system (NCT03402425). Results: Using follow-up (93%) or re-operation (7%) as reference standard, PET combined with MRI discriminated tumor from treatment effects with a lesion based sensitivity/specificity/accuracy (95% confidence intervals) of 0.73(0.50-1.00)/1.00(0.74-1.00)/0.87(0.73-1.00) compared to MRI alone: 0.80(0.57-1.00)/0.75(0.53-0.94)/0.77(0.65-0.90), i.e. the specificity for PET/MRI was 1.00 as compared to 0.75 for MRI alone (P = 0.13). In 11 of 27 cases (41%), results from the 18F-FET PET scans added relevant clinical information including one scan that directly influenced clinical management as an additional residual tumor site was identified. 18F-FET uptake in reactive changes was frequent (52%) but correct interpretation was possible in all cases. Conclusion: The high specificity for detecting residual tumor suggests that supplementary 18F-FET PET is relevant in cases where re-operation for residual tumor is considered.

U2 - 10.2967/jnumed.118.220293

DO - 10.2967/jnumed.118.220293

M3 - Journal article

VL - 60

SP - 1053

EP - 1058

JO - The Journal of Nuclear Medicine

JF - The Journal of Nuclear Medicine

SN - 0161-5505

IS - 8

ER -

ID: 217613868